An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia - Full report

Scott M Grundy; Hidenori Arai; Philip Barter; Thomas P. Bersot; D. John Betteridge; Rafael Carmena; Ada Cuevas; Michael H. Davidson; Jacques Genest; Y. Antero Kesäniemi; Shaukat Sadikot; Raul D. Santos; Andrey V. Susekov; Rody G. Sy; S. LaleTokgözoglu; Gerald F. Watts; Dong Zhao

doi:10.1016/j.jacl.2013.12.005

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia - Full report

Scott M Grundy, Hidenori Arai, Philip Barter, Thomas P. Bersot, D. John Betteridge, Rafael Carmena, Ada Cuevas, Michael H. Davidson, Jacques Genest, Y. Antero Kesäniemi, Shaukat Sadikot, Raul D. Santos, Andrey V. Susekov, Rody G. Sy, S. LaleTokgözoglu, Gerald F. Watts, Dong Zhao

Research output: Contribution to journal › Article › peer-review

298 Scopus citations

Abstract

An international panel of the International Atherosclerosis Society has developed a new set of recommendations for the management of dyslipidemia. The panel identifies non - high-density lipoprotein cholesterol as the major atherogenic lipoprotein. Primary and secondary prevention are considered separately. Optimal levels for atherogenic lipoproteins are derived for the two forms of prevention. For primary prevention, the recommendations emphasize lifestyle therapies to reduce atherogenic lipoproteins; drug therapy is reserved for subjects at greater risk. Risk assessment is based on estimation of lifetime risk according to differences in baseline population risk in different nations or regions. Secondary prevention emphasizes use of cholesterol-lowering drugs to attain optimal levels of atherogenic lipoproteins.

Original language	English (US)
Pages (from-to)	29-60
Number of pages	32
Journal	Journal of Clinical Lipidology
Volume	8
Issue number	1
DOIs	https://doi.org/10.1016/j.jacl.2013.12.005
State	Published - Jan 2014

Keywords

Cholesterol
Dyslipidemia
Lifestyle therapies
Lifetime risk
Metabolic syndrome
Statins

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Nutrition and Dietetics
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacl.2013.12.005

Cite this

Grundy, S. M., Arai, H., Barter, P., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A., Davidson, M. H., Genest, J., Kesäniemi, Y. A., Sadikot, S., Santos, R. D., Susekov, A. V., Sy, R. G., LaleTokgözoglu, S., Watts, G. F., & Zhao, D. (2014). An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia - Full report. Journal of Clinical Lipidology, 8(1), 29-60. https://doi.org/10.1016/j.jacl.2013.12.005

Grundy, SM, Arai, H, Barter, P, Bersot, TP, Betteridge, DJ, Carmena, R, Cuevas, A, Davidson, MH, Genest, J, Kesäniemi, YA, Sadikot, S, Santos, RD, Susekov, AV, Sy, RG, LaleTokgözoglu, S, Watts, GF & Zhao, D 2014, 'An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia - Full report', Journal of Clinical Lipidology, vol. 8, no. 1, pp. 29-60. https://doi.org/10.1016/j.jacl.2013.12.005

@article{3e3dbe820b1542a6a174d1a616a320cf,

title = "An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia - Full report",

abstract = "An international panel of the International Atherosclerosis Society has developed a new set of recommendations for the management of dyslipidemia. The panel identifies non - high-density lipoprotein cholesterol as the major atherogenic lipoprotein. Primary and secondary prevention are considered separately. Optimal levels for atherogenic lipoproteins are derived for the two forms of prevention. For primary prevention, the recommendations emphasize lifestyle therapies to reduce atherogenic lipoproteins; drug therapy is reserved for subjects at greater risk. Risk assessment is based on estimation of lifetime risk according to differences in baseline population risk in different nations or regions. Secondary prevention emphasizes use of cholesterol-lowering drugs to attain optimal levels of atherogenic lipoproteins.",

keywords = "Cholesterol, Dyslipidemia, Lifestyle therapies, Lifetime risk, Metabolic syndrome, Statins",

author = "Grundy, {Scott M} and Hidenori Arai and Philip Barter and Bersot, {Thomas P.} and Betteridge, {D. John} and Rafael Carmena and Ada Cuevas and Davidson, {Michael H.} and Jacques Genest and Kes{\"a}niemi, {Y. Antero} and Shaukat Sadikot and Santos, {Raul D.} and Susekov, {Andrey V.} and Sy, {Rody G.} and S. LaleTokg{\"o}zoglu and Watts, {Gerald F.} and Dong Zhao",

year = "2014",

month = jan,

doi = "10.1016/j.jacl.2013.12.005",

language = "English (US)",

volume = "8",

pages = "29--60",

journal = "Journal of Clinical Lipidology",

issn = "1933-2874",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - An International Atherosclerosis Society Position Paper

T2 - Global recommendations for the management of dyslipidemia - Full report

AU - Grundy, Scott M

AU - Arai, Hidenori

AU - Barter, Philip

AU - Bersot, Thomas P.

AU - Betteridge, D. John

AU - Carmena, Rafael

AU - Cuevas, Ada

AU - Davidson, Michael H.

AU - Genest, Jacques

AU - Kesäniemi, Y. Antero

AU - Sadikot, Shaukat

AU - Santos, Raul D.

AU - Susekov, Andrey V.

AU - Sy, Rody G.

AU - LaleTokgözoglu, S.

AU - Watts, Gerald F.

AU - Zhao, Dong

PY - 2014/1

Y1 - 2014/1

N2 - An international panel of the International Atherosclerosis Society has developed a new set of recommendations for the management of dyslipidemia. The panel identifies non - high-density lipoprotein cholesterol as the major atherogenic lipoprotein. Primary and secondary prevention are considered separately. Optimal levels for atherogenic lipoproteins are derived for the two forms of prevention. For primary prevention, the recommendations emphasize lifestyle therapies to reduce atherogenic lipoproteins; drug therapy is reserved for subjects at greater risk. Risk assessment is based on estimation of lifetime risk according to differences in baseline population risk in different nations or regions. Secondary prevention emphasizes use of cholesterol-lowering drugs to attain optimal levels of atherogenic lipoproteins.

AB - An international panel of the International Atherosclerosis Society has developed a new set of recommendations for the management of dyslipidemia. The panel identifies non - high-density lipoprotein cholesterol as the major atherogenic lipoprotein. Primary and secondary prevention are considered separately. Optimal levels for atherogenic lipoproteins are derived for the two forms of prevention. For primary prevention, the recommendations emphasize lifestyle therapies to reduce atherogenic lipoproteins; drug therapy is reserved for subjects at greater risk. Risk assessment is based on estimation of lifetime risk according to differences in baseline population risk in different nations or regions. Secondary prevention emphasizes use of cholesterol-lowering drugs to attain optimal levels of atherogenic lipoproteins.

KW - Cholesterol

KW - Dyslipidemia

KW - Lifestyle therapies

KW - Lifetime risk

KW - Metabolic syndrome

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84893935789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893935789&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2013.12.005

DO - 10.1016/j.jacl.2013.12.005

M3 - Article

C2 - 24528685

AN - SCOPUS:84893935789

SN - 1933-2874

VL - 8

SP - 29

EP - 60

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

IS - 1

ER -

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia - Full report

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this